Periungal hyperpigmentation induced by cisplatin

Clinical and Experimental Dermatology

Volumn 27, Issue 2, 2002, Pages 118-119

  Kim, K J ^a   Chang, S E ^a   Choi, J H ^a   Sung, K J ^a   Moon, K C ^a   Koh, J K ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CISPLATIN;

AGED; ARTICLE; ARTIFICIAL EMBOLISM; CASE REPORT; CLINICAL FEATURE; DRUG TOLERABILITY; FOOT; HAND; HEPATITIS B; HUMAN; HUMAN TISSUE; HYPERPIGMENTATION; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; SKIN EXAMINATION;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CISPLATIN; DRUG ERUPTIONS; FOOT; HAND; HUMANS; HYPERPIGMENTATION; LIVER NEOPLASMS; MALE;

EID: 0036040785     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.2002.00972.x     Document Type: Article

References (5)

1. Persistent serpentine supravenous hyperpigmented eruption as an adverse reaction to chemotherapy combining actinomycin and vincristine
2. Dermatologic changes after systemic cancer therapy
3. Ifosfamide-induced hyperpigmentation
4. Localized cisplatin hyperpigmentation induced by pressure
5. Pediatric osteosarcoma. Treatment of the primary tumor with intra-arterial cis-diamminedichloroplatinum II (CDP) - Advantages, disadvantages and controversial issues